All In Biotech

NDA 018936 · Eli Lilly and CO

Sarafem

Fluoxetine Hydrochloride · Oral

NovelPriority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Dec 29, 1987

Approved uses

10

Original approval plus efficacy supplements

Registered trials

326

58 Phase 3, 28 recruiting

FAERS reports

63,050

39,616 serious, 3,988 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions ( 5.1 )] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions ( 5.1 )] . PROZAC is not approved for use in children less than 7 years of age [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )] . When using PROZAC...

What it is approved for

From the label in effect Jan 8, 2026.

PROZAC ® is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies ( 14.1 )] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies ( 14.2 )]. Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies ( 14.3 )] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies ( 14.4 )]. PROZAC and Olanzapine in Combination is indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). PROZAC monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using PROZAC and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . PROZAC ® is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) PROZAC and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )

Mechanism: Although the exact mechanism of PROZAC is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • SARAFEM · FLUOXETINE HYDROCHLORIDE EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • PROZAC · FLUOXETINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE, ORAL · Discontinued · TE AB1
  • PROZAC · FLUOXETINE HYDROCHLORIDE EQ 60MG BASE · CAPSULE, ORAL · Discontinued
  • SARAFEM · FLUOXETINE HYDROCHLORIDE EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • PROZAC · FLUOXETINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, ORAL · Discontinued · TE AB
  • PROZAC · FLUOXETINE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, ORAL · Discontinued · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluoxetine" as an intervention, any sponsor and status, largest first.

All 326 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,661
  • fatigue4,344
  • nausea4,301
  • headache3,758
  • depression3,706
  • anxiety3,422
  • pain3,103
  • dizziness2,925
  • diarrhoea2,863
  • off label use2,734
  • insomnia2,671
  • dyspnoea2,641

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,705
20051,710
20061,680
20071,443
20081,409
20091,920
20102,252
20112,519
20123,268
20132,581
20142,868
20155,363
20164,442
20173,305
20183,296
20193,332
20202,801
20212,462
20223,084
20232,963
20243,226
20253,036
20262,383

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prozac (Fluoxetine HCl)

2024 spending

$15.6M

Beneficiaries

2,183

11,749 claims

Per beneficiary

$7,169

$17.78 per unit

View as table
YearSpending
2020$25,021,067
2021$23,665,005
2022$23,441,957
2023$22,023,208
2024$15,649,211

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,245 on PubMed

Sponsor: Eli Lilly · Also marketed as Prozac

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.